Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing.
Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.
Department of Medicine, The University of Manchester, 1.800 Stopford Building, Oxford Road, Manchester, UK. william.hope@manchester.ac.uk
William W
WW
Hope
Peter A
PA
Warn
Andrew
A
Sharp
Paul
P
Reed
Brian
B
Keevil
Arnold
A
Louie
Thomas J
TJ
Walsh
David W
DW
Denning
George L
GL
Drusano
D000465:Algorithms; D000666:Amphotericin B / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D004347:Drug Interactions; D005437:Flucytosine / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D015233:Models, Statistical; D009010:Monte Carlo Method
D000935:Antifungal Agents; D000666:Amphotericin B; D005437:Flucytosine